Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid

Abstract

The lenvatinib PFS benefit was maintained regardless of baseline CAF or BRAF/RAS status. Baseline Ang2 was predictive of PFS in a subgroup of lenvatinib-treated patients, indicating that Ang2 may be predictive of lenvatinib sensitivity. BRAF may be a poor prognostic factor in patients with radioiodine-refractory papillary thyroid cancer. Improved PFS associated with upregulated FGF23 suggests that lenvatinib-induced FGF receptor inhibition contributes to lenvatinib efficacy. Trial registration ID of the main study, SELECT: ClinicalTrials.gov: NCT01321554.

Sequential Analysis of Neutrophil-to-lymphocyte Ratio for Differentiated Thyroid Cancer Patients Treated With Lenvatinib

“…Thyroglobulin levels have also been studied as a tumor marker for DTC (16). In the SELECT trial, baseline thyroglobulin levels were associated with poorer PFS in RR-DTC (17). It has been reported that a shorter thyroglobulin doubling time (<1 year) in patients is associated with a poor prognosis (18).…”

Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma

“…Thus, lenvatinib cannot be simply said to be a promising Another index of efficacy in thyroid carcinoma is serum Tg [14]. Whereas morphologic assessment is routinely adopted to evaluate treatment efficacy, the role of serum Tg is not entirely clear.…”

Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice

“…Similarly, lenvatinib was associated with antitumor activity in advanced glioblastoma (32). Biomarkers predicting the efficacy of antiangiogenetic agents include p-VEGFR2 expression in advanced breast cancer and angiopoietin 2 expression in differentiated cancer of the thyroid (33,34). Further investigations are warranted to determine which tumors respond to antiangiogenesis inhibitors, including lenvatinib.…”